Ipamorelin Dosage: What Community Protocols Report
Last updated September 27, 2026 · Reviewed by Grey Peptides Editorial Board · ✓ Primary-sourced
← Ipamorelin encyclopedia entry · See also: CJC-1295 dosage · Sermorelin dosage
Ipamorelin is investigational and was never FDA approved; its drug development was discontinued. There is no label, no official dose, and no titration schedule. The amounts below are community and compounding-practice figures, documented for education — not instructions for use. An unapproved injectable carries unknowns of identity, purity, and sterility.
Educational information, not medical advice. The doses on this page come from approved labels, published studies and, where no study exists, amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
The short version
Ipamorelin is a growth-hormone-releasing peptide (a ghrelin-receptor agonist). Its claim to fame is selectivity: in its original characterization it triggered growth-hormone release with minimal effect on cortisol, prolactin, and ACTH — unlike older GHRPs such as GHRP-6. That "clean" profile is why it became a community favorite, usually paired with a GHRH analog. But selectivity is a pharmacology point, not a regulatory one: there is no approved ipamorelin product, so all dosing is extrapolated from early research and practice.
What community protocols report
The most commonly cited pattern is small microgram doses given once to a few times daily. These are descriptive, not prescriptive.
Community-reported. Amounts users report, recorded for education. Not a recommendation, and not a dose any study has shown to be safe or effective.
| Parameter | Commonly reported |
|---|---|
| Amount | ~100–300 mcg per dose |
| Frequency | 1–3× daily |
| Timing | Pre-bed and/or post-workout |
| Route | Subcutaneous |
The timing logic mirrors the body's own rhythm — growth-hormone pulses peak in deep sleep and after exercise — and ipamorelin's short half-life (on the order of a couple of hours) is the rationale offered for multiple daily doses. Again, this is reasoning from mechanism, not from approval-grade human trials.
The CJC-1295 pairing
Ipamorelin is most often discussed alongside CJC-1295, a GHRH analog. The theory is complementary mechanisms — a GHRH analog raises the baseline drive while the GHRP triggers a pulse — but the combination has not been tested for safety or efficacy in approval-grade human studies any more than the individual compounds have. See the CJC-1295 dosage page for how that side is framed.
Reconstitution basics
Ipamorelin is supplied as a lyophilized powder requiring reconstitution with bacteriostatic water before microgram doses can be measured. The small amounts make dilution errors easy, so the arithmetic matters: the Reconstitution Calculator converts vial strength and diluent volume into an exact draw, and the Half-Life Visualizer illustrates how a short half-life shapes levels across a day. A calculator handles the math but cannot verify what is in the vial.
Frequently asked questions
Why multiple doses a day?
The short half-life is the usual rationale, on the idea that each dose triggers a discrete GH pulse. This is convention drawn from pharmacology rather than a validated schedule.
Is more better?
Beyond a certain point, GH-releasing peptides show a saturable response — extra drug does not produce proportionally more release — which is part of why protocols cluster in the low microgram range rather than escalating freely.
Is ipamorelin legal?
It is not an approved medicine; FDA placed it in 503B Category 2 (significant safety risks) on September 29, 2023, and its 503A nomination was withdrawn, so no pharmacy or outsourcing facility may compound it (FDA lists re-read September 26, 2026). Status varies by jurisdiction — see the Regulatory Status Tracker.
Sources
- Raun K, et al. "Ipamorelin, the first selective growth hormone secretagogue." Eur J Endocrinol. 1998;139:552–561.
- Sinha DK, et al. Review of growth-hormone secretagogues and their pharmacology.
Medical disclaimer: Education only, not medical advice. Ipamorelin is investigational and not approved for human use. Dosing figures reflect community/compounding practice, not a recommendation. Do not self-administer; consult a licensed clinician.